CoChat

Phase IB Study of Vemurafenib in Combination with Irinotecan and Cetuximab in Patients with Metastatic Colorectal Cancer with BRAF V600E Mutation

Open access

Published version of a preprint

The DOI matches its Crossref record; 32 of the 32 references it cites were found in a registry or an index.

Abstract

In vitro, EGFR inhibition, combined with the BRAF inhibitor vemurafenib, causes synergistic cytotoxicity for BRAFV600E metastatic colorectal cancer, further augmented by irinotecan. The safety and efficacy of vemurafenib, irinotecan, and cetuximab in BRAF-mutated malignancies are not defined. In this 3+3 phase I study, patients with BRAFV600E-advanced solid cancers received cetuximab and irinotecan with escalating doses of vemurafenib. Nineteen patients (18 with metastatic colorectal cancer and 1 with appendiceal cancer) were enrolled. Three patients experienced dose-limiting toxicities. The MTD of vemurafenib was 960 mg twice daily. Six of 17 evaluable patients (35%) achieved a radiographic response by Response Evaluation Criteria in Solid Tumors 1.1 criteria, consistent with in vivo models demonstrating tumor regressions with the triplet regimen. Median progression-free survival was 7.7 months. BRAFV600E circulating cell-free DNA (cfDNA) trends correlated with radiographic changes, and acquired mutations from cfDNA in genes reactivating MAPK signaling were observed at progression. Significance: Vemurafenib, in combination with irinotecan and cetuximab, was well tolerated in patients with refractory, BRAF-mutated metastatic colorectal cancer, and both survival outcomes and response rates exceeded prior reports for vemurafenib and for irinotecan plus cetuximab in BRAFV600E metastatic colorectal cancer. In vivo models demonstrated regressions with the triplet, in contrast with vemurafenib and cetuximab alone. cfDNA predicted radiographic response and identified mutations reactivating the MAPK pathway upon progression. Cancer Discov; 6(12); 1352–65. ©2016 AACR. This article is highlighted in the In This Issue feature, p. 1293

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1158/2159-8290.cd-16-0050

Cites

32 of 32 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 32 references

Cited by

See all 234

Metadata

Authors
Hong, D. S., Morris, V. K., El Osta, B., Sorokin, A. V., Janku, F., Fu, S., Overman, M. J., Piha-Paul, S., Subbiah, V., Kee, B., Tsimberidou, A. M., Fogelman, D., Bellido, J., Shureiqi, I., Huang, H., Atkins, J., Tarcic, G., Sommer, N., Lanman, R., Meric-Bernstam, F., & Kopetz, S.
Affiliations
  • The University of Texas MD Anderson Cancer Center (US)
  • 3Department of Hematology and Medical Oncology, Atlanta Veterans Affairs Medical Center, Emory University School of Medicine, Atlanta, Georgia.
  • 1Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • 4NovellusDx, Jerusalem, Israel.
  • Genentech (US)
  • Guardant (United States) (US)
Corresponding author
Hong, David S.
Venue
Cancer Discovery
Published
2016-12-01
Volume
6
Issue
12
Pages
1352-1365
ISSN
  • 2159-8274 (ISSN-L)
  • 2159-8290
OpenAlex
W2530590137
Cited by
219
References
32
Citations by year
2026: 8 · 2025: 6 · 2024: 14 · 2023: 20 · 2022: 18 · 2021: 29 · 2020: 45 · 2019: 28 · 2018: 24 · 2017: 26 · 2016: 1
FWCI
14.18
Type
journal article
Language
en
Open access
Locations
  • Cancer Discovery (publishedVersion)
  • PubMed (publishedVersion)
  • PubMed Central (acceptedVersion)
Funders
NCI (R01CA187238, R01CA172670, R01CA184843)
Topics
  • Health Sciences › Medicine › Oncology › Colorectal Cancer Treatments and Studies
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Melanoma and MAPK Pathways
  • Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
Keywords
vemurafenib, irinotecan, cetuximab, BRAF V600E mutation, metastatic colorectal cancer, combination therapy, dose-limiting toxicity, maximum tolerated dose, cell-free DNA, MAPK pathway reactivation, EGFR inhibition, tumor response prediction, refractory cancer
MeSH terms
Cetuximab, Irinotecan, Vemurafenib, Animals, Antineoplastic Combined Chemotherapy Protocols, Camptothecin, Drug Administration Schedule, Female, Humans, Indoles, Male, Mutation, Neoplasm Metastasis, Sulfonamides, Colorectal Neoplasms, Survival Analysis, Treatment Outcome, Disease-Free Survival, Xenograft Model Antitumor Assays, Cell Line, Tumor, Proto-Oncogene Proteins B-raf, Mice

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Phase IB Study of Vemurafenib in Combination with Irinotecan and Cetuximab in Patients with Metastatic Colorectal Cancer with BRAF V600E Mutation. https://app.cochat.ai/papers/10.1158/2159-8290.cd-16-0050
The paper
Hong, D. S., Morris, V. K., El Osta, B., Sorokin, A. V., Janku, F., Fu, S., Overman, M. J., Piha-Paul, S., Subbiah, V., Kee, B., Tsimberidou, A. M., Fogelman, D., Bellido, J., Shureiqi, I., Huang, H., Atkins, J., Tarcic, G., Sommer, N., Lanman, R., . . . Kopetz, S. (2016). Phase IB Study of Vemurafenib in Combination with Irinotecan and Cetuximab in Patients with Metastatic Colorectal Cancer with BRAF V600E Mutation. Cancer Discovery. https://doi.org/10.1158/2159-8290.cd-16-0050

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.